Temodar Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Condition:   Neuroblastoma Interventions:   Drug: Naxitamab monotherapy;   Drug: GM-CSF;   Drug: Irinotecan;   Drug: Temozolomide;   Drug: Naxitamab in combination therapy;   Drug: GM-CSF with combination regimen;   Drug: Sintilimab Sponsors:   Sun Yat-sen University;   Hainan General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Condition:   Neuroblastoma Interventions:   Drug: Naxitamab monotherapy;   Drug: GM-CSF;   Drug: Irinotecan;   Drug: Temozolomide;   Drug: Naxitamab in combination therapy;   Drug: GM-CSF with combination regimen;   Drug: Sintilimab Sponsor:   Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2023 Category: Research Source Type: clinical trials

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Conditions:   Malignant Neoplasm;   Malignant Neoplasm of Brain Interventions:   Drug: NBM-BMX Capsule;   Drug: Temozolomide;   Radiation: Standard radiotherapy Sponsor:   NatureWise Biotech & Medicals Corporation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials